225 Second Avenue
About BioverativLaunching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.
CEO: John Cox
Currently there are no jobs for this employer.
Browse all jobs here